Viatris' Ambitious Play for Japan's Nephropathy Market The latest results from a Phase 3 clinical trial of VR 205, Viatris' targeted release budesonide treatment for primary immunoglobulin A nephropathy (IgAN), have sent shockwaves through the pharmaceutical industry.
The study demonstrated a significant reduction in urine protein to creatinine ratio and improvements in kidney function, raising hopes of a potential breakthrough in addressing Japan's high incidence of IgAN.
Viatris' decision to pursue regulatory approval for VR 205 in Japan by 2026 is a strategic move that highlights the company's commitment to addressing unmet medical needs.